Jiahe Zheng1, Zubin Irani2, Donald Lawrence3, Keith Flaherty3, Ronald S Arellano4. 1. Department of Radiology, ShengJing Hospital of China Medical University, Shenyang City, People's Republic of China; Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114. 2. Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114. 3. Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts. 4. Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114. Electronic address: rarellano@mgh.harvard.edu.
Abstract
PURPOSE: To evaluate the safety and efficacy of yttrium-90 (90Y) transarterial radioembolization (TARE) around immunotherapy in patients with unresectable hepatic metastases from uveal melanoma (UM). MATERIALS AND METHODS: From March 2013 to December 2017, 11 patients with unresectable hepatic metastases from UM were treated with TARE around immunotherapy. Two patients received TARE as a first-line treatment followed by immunotherapy. Nine patients received immunotherapy before TARE, and 6 of these patients received additional immunotherapy after TARE. Retrospective review of the clinical data was performed to assess hepatic progression-free survival (hPFS), overall survival (OS), treatment response, and toxicities. The median follow-up period from TARE was 10.5 months (range 1-35.5 months). RESULTS: The median OS from diagnosis of hepatic metastases was 35.5 months (95% confidence interval [CI] 10.0-55.0 months). The median hPFS and OS from the start of TARE were 15.0 months (95% CI 5.9-24.1 months) and 17.0 months (95% CI 1.8-32.2 months), respectively. Complete response was observed in 1 patient (9.1%), partial response in 2 (18.2%), stable disease in 4 (36.4%), and progressive disease in 4 (36.4%). Ten patients had grade 1 or 2 clinical toxicities, and 1 had grade 3 with a peptic ulcer. Six patients had grade 1 or 2 biochemical toxicities and 1 had grade 3, which was related to tumor progression. CONCLUSIONS: The present results suggest that TARE around immunotherapy is safe and effective. The combined treatment may improve hPFS and OS in patients with hepatic metastases from UM.
PURPOSE: To evaluate the safety and efficacy of yttrium-90 (90Y) transarterial radioembolization (TARE) around immunotherapy in patients with unresectable hepatic metastases from uveal melanoma (UM). MATERIALS AND METHODS: From March 2013 to December 2017, 11 patients with unresectable hepatic metastases from UM were treated with TARE around immunotherapy. Two patients received TARE as a first-line treatment followed by immunotherapy. Nine patients received immunotherapy before TARE, and 6 of these patients received additional immunotherapy after TARE. Retrospective review of the clinical data was performed to assess hepatic progression-free survival (hPFS), overall survival (OS), treatment response, and toxicities. The median follow-up period from TARE was 10.5 months (range 1-35.5 months). RESULTS: The median OS from diagnosis of hepatic metastases was 35.5 months (95% confidence interval [CI] 10.0-55.0 months). The median hPFS and OS from the start of TARE were 15.0 months (95% CI 5.9-24.1 months) and 17.0 months (95% CI 1.8-32.2 months), respectively. Complete response was observed in 1 patient (9.1%), partial response in 2 (18.2%), stable disease in 4 (36.4%), and progressive disease in 4 (36.4%). Ten patients had grade 1 or 2 clinical toxicities, and 1 had grade 3 with a peptic ulcer. Six patients had grade 1 or 2 biochemical toxicities and 1 had grade 3, which was related to tumor progression. CONCLUSIONS: The present results suggest that TARE around immunotherapy is safe and effective. The combined treatment may improve hPFS and OS in patients with hepatic metastases from UM.
Authors: Carin F Gonsalves; David J Eschelman; Robert D Adamo; P Rani Anne; Marlana M Orloff; Mizue Terai; Anthony N Hage; Misung Yi; Inna Chervoneva; Takami Sato Journal: Radiology Date: 2019-08-27 Impact factor: 11.105
Authors: Harry Alexander; Daniel Wen; Michael Chu; Catherine Han; Peter Hadden; Robert Thomas; Adam Bartlett Journal: Br J Radiol Date: 2021-11-10 Impact factor: 3.039
Authors: Vivian Chua; Jane Mattei; Anna Han; Lauren Johnston; Kyleigh LiPira; Sara M Selig; Richard D Carvajal; Andrew E Aplin; Sapna P Patel Journal: Clin Cancer Res Date: 2020-10-15 Impact factor: 12.531
Authors: T M L Tong; M K van der Kooij; F M Speetjens; A R van Erkel; R W van der Meer; J Lutjeboer; E L van Persijn van Meerten; C H Martini; R W M Zoethout; F G J Tijl; C U Blank; M C Burgmans; E Kapiteijn Journal: Trials Date: 2022-02-13 Impact factor: 2.279
Authors: Maria Sofia Basile; Emanuela Mazzon; Paolo Fagone; Antonio Longo; Andrea Russo; Matteo Fallico; Vincenza Bonfiglio; Ferdinando Nicoletti; Teresio Avitabile; Michele Reibaldi Journal: Front Oncol Date: 2019-11-05 Impact factor: 6.244